Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Head-to-head evaluation on diagnostic accuracies of six SARS-CoV-2 serological assays
Shaun Shi Yan Tan, Sharon Saw, Ka Lip Chew, et al.
Pathology (2020) Vol. 52, Iss. 7, pp. 770-777
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection
Sean C. Taylor, Beth Hurst, Carmen Charlton, et al.
Journal of Clinical Microbiology (2021) Vol. 59, Iss. 4
Open Access | Times Cited: 140
Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Serologic Testing
Mary K. Hayden, Ibrahim K El Mikati, Kimberly E. Hanson, et al.
Clinical Infectious Diseases (2024)
Open Access | Times Cited: 62
Utility of Different Surrogate Enzyme-Linked Immunosorbent Assays (sELISAs) for Detection of SARS-CoV-2 Neutralizing Antibodies
Niko Kohmer, Cornelia Rühl, Sandra Ciesek, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 10, pp. 2128-2128
Open Access | Times Cited: 60
SARS‐CoV‐2 seroprevalence among blood donors after the first COVID‐19 wave in Canada
Sahar Saeed, Steven J. Drews, Chantale Pambrun, et al.
Transfusion (2021) Vol. 61, Iss. 3, pp. 862-872
Open Access | Times Cited: 55
Comprehensive Comparison of Seven SARS-CoV-2-Specific Surrogate Virus Neutralization and Anti-Spike IgG Antibody Assays Using a Live-Virus Neutralization Assay as a Reference
Marianne Graninger, Claudia Jani, Elisabeth Reuberger, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 26
Head-to-head comparison of two rapid high-throughput automated electrochemiluminescence immunoassays targeting total antibodies to the SARS-CoV-2 nucleoprotein and spike protein receptor binding domain
Mario Poljak, Anja Oštrbenk Valenčak, Tina Štamol, et al.
Journal of Clinical Virology (2021) Vol. 137, pp. 104784-104784
Open Access | Times Cited: 40
Function Is More Reliable than Quantity to Follow Up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 Vaccination
Carlos A. Sariol, Petraleigh Pantoja, Crisanta Serrano-Collazo, et al.
Viruses (2021) Vol. 13, Iss. 10, pp. 1972-1972
Open Access | Times Cited: 32
Perspective: diagnostic laboratories should urgently develop T cell assays for SARS-CoV-2 infection
Rohan Ameratunga, See-Tarn Woon, A. M. Jordan, et al.
Expert Review of Clinical Immunology (2021) Vol. 17, Iss. 5, pp. 421-430
Closed Access | Times Cited: 30
A rapid simple point-of-care assay for the detection of SARS-CoV-2 neutralizing antibodies
Patthara Kongsuphol, Huan Jia, Hoi Lok Cheng, et al.
Communications Medicine (2021) Vol. 1, Iss. 1
Open Access | Times Cited: 29
Evaluation of serum and urine biomarkers for severe COVID-19
Yaroslav D. Shansky, Oleg O. Yanushevich, Alina V. Gospodarik, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 3
Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19–Convalescent Donors
Bernd Jahrsdörfer, Rüdiger Groß, Alina Seidel, et al.
The Journal of Immunology (2021) Vol. 206, Iss. 11, pp. 2614-2622
Open Access | Times Cited: 24
Evaluation of Dried Blood Spot Testing for SARS-CoV-2 Serology Using a Quantitative Commercial Assay
Davor Brinc, Mia J. Biondi, Daniel Li, et al.
Viruses (2021) Vol. 13, Iss. 6, pp. 962-962
Open Access | Times Cited: 24
Anti-SARS-CoV-2 equine F (Ab′)2 immunoglobulin as a possible therapy for COVID-19
Viviane Fongaro Botosso, Soraia Attie Calil Jorge, Renato Mancini Astray, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 14
Serology surveillance of SARS-CoV-2 antibodies among healthcare workers in COVID-19 designated facilities in Malaysia
Yuan Liang Woon, Yee Leng Lee, Yoong Min Chong, et al.
The Lancet Regional Health - Western Pacific (2021) Vol. 9, pp. 100123-100123
Open Access | Times Cited: 19
Seroprevalence of severe acute respiratory syndrome coronavirus 2 in Slovenia: results of two rounds of a nationwide population study on a probability-based sample, challenges and lessons learned
Mario Poljak, Anja Oštrbenk Valenčak, Erik Štrumbelj, et al.
Clinical Microbiology and Infection (2021) Vol. 27, Iss. 7, pp. 1039.e1-1039.e7
Open Access | Times Cited: 19
Evolution of antibodies against SARS-CoV-2 over seven months: Experience of the nationwide seroprevalence ENE-COVID study in Spain
Mayte Pérez‐Olmeda, José María Saugar, Aurora Fernández-García, et al.
Journal of Clinical Virology (2022) Vol. 149, pp. 105130-105130
Open Access | Times Cited: 12
Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS-CoV-2 Spike protein after natural infection or COVID-19 vaccination
Carlos A. Sariol, Petraleigh Pantoja, Crisanta Serrano-Collazo, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 17
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard
Sahar Saeed, Sheila F. O’Brien, Kento T. Abe, et al.
PLoS ONE (2021) Vol. 16, Iss. 9, pp. e0257743-e0257743
Open Access | Times Cited: 15
Semi-quantitative, high throughput analysis of SARS-CoV-2 neutralizing antibodies: Measuring the level and duration of immune response antibodies post infection/vaccination
Sean C. Taylor, Beth Hurst, Ian Martiszus, et al.
Vaccine (2021) Vol. 39, Iss. 39, pp. 5688-5698
Open Access | Times Cited: 14
SARS‐CoV‐2 infections among pregnant women, 2020, Finland—Cross‐testing of neutralization assays
Jenni Virtanen, Essi M. Korhonen, Sami Salonen, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 2
Open Access | Times Cited: 1
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children
Eder Gatti Fernandes, Giselle Ibete Silva López‐Lopes, Valéria Oliveira Silva, et al.
Revista do Instituto de Medicina Tropical de São Paulo (2021) Vol. 63
Open Access | Times Cited: 11
Performance Characteristics of High-Throughput Serologic Assays for Severe Acute Respiratory Syndrome Coronavirus 2 with Food and Drug Administration Emergency Use Authorization
Elitza S. Theel
Clinics in Laboratory Medicine (2021) Vol. 42, Iss. 1, pp. 15-29
Open Access | Times Cited: 10
Practical Considerations for Implementation of SARS-CoV-2 Serological Testing in the Clinical Laboratory: Experience at an Academic Medical Center
Robert Humble, Anna E. Merrill, Bradley Ford, et al.
Academic Pathology (2021) Vol. 8, pp. 23742895211002802-23742895211002802
Open Access | Times Cited: 9
Performance and correlation of ten commercial immunoassays for the detection of SARS-CoV-2 antibodies
Dewi Lokida, Muhammad Karyana, Herman Kosasih, et al.
Heliyon (2022) Vol. 8, Iss. 12, pp. e12614-e12614
Open Access | Times Cited: 6
Performance of 4 Automated SARS-CoV-2 Serology Assay Platforms in a Large Cohort Including Susceptible COVID-19–Negative and COVID-19–Positive Patients
Matthew Ward, Kristin Mullins, Elizabeth Pickett, et al.
The Journal of Applied Laboratory Medicine (2021) Vol. 6, Iss. 4, pp. 942-952
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top